Dr. Dottino on Targeted Therapies in Ovarian Cancer

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

There are PARP inhibitors and VEGF inhibitors are targeted therapies that are available today, but others are being investigated in phase I/II trials that will be potentially of use, explains Dottino.

According to Dottino in a study investigating p53-mutated patients using AZD1775 with carboplatin in platinum-refractory patients, a 46% response rate was observed.